Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label placebo for antidepressant discontinuation symptoms
NCT05051995Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Feb 2022
- Primary completion
- Feb 2024
- Countries
- 1
01
Overview
Randomised, open-label trial of Placebo-COD Research Private Ltd in Antidepressant discontinuation syndrome (ADS) (2 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Generic rating scale for treatment effects at 8 weeks. Started Feb 2022; status: completed.
02
Drugs
Placebo-COD Research Private Ltd
03
Conditions
Antidepressant discontinuation syndrome (ADS)
Beyond the preview
Go deeper on NCT05051995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05051995.